In ₹ Crore except Per Share Latest Annual | JENBURPH FY26 | BPLPHARMA FY23 | KPL FY24 | MAKERSL FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | 37.02× | — | — | 37.02× | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 7.26% | — | — | 5.77% | 5.77% +26% | |
| Revenue CAGR 5Y | ◆ 9.07% | — | — | 1.55% | 1.55% +485% | |
| Net Income CAGR 3Y | 12.18% | — | — | — | — | |
| Profitability | ||||||
| EBITDA Margin | ◆ 23.81% | 9.80% | 21.69% | 1.45% | 9.80% +143% | |
| Net Income Margin | ◆ 20.59% | 11.16% | — | -3.42% | 3.87% +432% | |
| Return on Common Equity | — | ◆ 12.74% | — | -3.16% | 4.79% | |
| Return on Capital Employed | — | — | 19.18% | — | 19.18% | |
| Return on Assets | ◆ 15.37% | 7.90% | — | -2.34% | 2.78% +453% | |
| Credit & Quality | ||||||
| Total Debt/Equity | — | ◆ 0.04× | 0.43× | 0.05× | 0.05× | |
| Interest Coverage | — | ◆ 7.10× | 4.54× | -3.91× | 4.54× | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹169 Cr | ₹218 Cr | ₹307 Cr | ₹50.3 Cr | ₹218 Cr -23% | |
| Net Income | ₹34.7 Cr | ₹24.3 Cr | — | −₹1.7 Cr | ₹11.3 Cr +207% | |
| Total Assets | ₹226 Cr | ₹308 Cr | ₹398 Cr | ₹73.5 Cr | ₹308 Cr -27% | |
| EPS | — | ₹42.14 | — | ₹-2.91 | ₹19.62 | |